This is the current release of the guideline.

Levels of evidence (I-IV) and grading of recommendations (A-D) are defined at the end of the Major Recommendations field.

Initial Assessment

• Repeated skin biopsies (ellipse rather than punch) are often required to confirm a diagnosis of cutaneous T-cell lymphoma (CTCL).
• Histology, immunophenotypic, and preferably T-cell receptor (TCR) gene analysis should be performed on all tissue samples (ideally molecular studies require fresh tissue).
• All patients (with the possible exception of early stage mycosis fungoides [stage IA] and lymphomatoid papulosis) should ideally be reviewed by an appropriate multidisciplinary team (MDT) for confirmation of the diagnosis and to establish a management strategy.
• Initial staging computed tomography (CT) scans are required in all patients with the exception of those with early stages of mycosis fungoides (stage IA/IB) and lymphomatoid papulosis.
• At diagnosis peripheral blood samples should be analysed for total white cell, lymphocyte, and Sézary cell counts, serum lactate dehydrogenase (LDH), liver and renal function, lymphocyte subsets, CD4/CD8 ratios, human T-cell lymphotropic virus (HTLV)-I serology and, preferably, TCR gene analysis.
• Bone marrow aspirate or trephine biopsies are required for CTCL variants (with the exception of lymphomatoid papulosis) and may also be appropriate for those with late stages of mycosis fungoides (stage IIB or above). (Grade A/Level III)

Histology

• The presence or absence of epidermotropism should be documented.
• The depth of the infiltrate should be noted.
• The morphology or cytology of the atypical cells and presence of large cell transformation, folliculotropism, syringotropism, granuloma formation, angiocentricity, and subcutaneous infiltration should be mentioned.
• Immunophenotypic studies should be performed on paraffin-embedded sections and include the T-cell markers CD2, CD3, CD4, CD8, B-cell marker CD20, and the activation marker CD30. Additional markers such as p53 may have prognostic significance in mycosis fungoides. Markers of cytotoxic function such as TIA-I, the monocyte/macrophage marker CD68 and natural killer (NK) cell marker CD56 may be useful for specific CTCL variants.
• Ideally all pathology results should be reviewed by a central panel (usually within cancer centres) as recommended for specialized pathology services.
• The histology, after correlation with the clinical features, should be classified according to an integration of the World Health Organization (WHO) and European Organization for Research and Treatment of Cancer (EORTC classification). (Grade A/Level III)

Prognosis

• Prognosis in mycosis fungoides (and clinical variants) is related to age at presentation (worse if >60 years), to the stage of the disease, and possibly to the presence of a peripheral blood T-cell clone; some mycosis fungoides clinical variants may have a better prognosis.
• In Sézary syndrome the median survival is 32 months from diagnosis.
• Primary cutaneous CD30+ lymphoproliferative disorders without peripheral nodal disease have an excellent prognosis (range 96-100% 5-year survival).
• The prognosis of other types of CTCL is generally poor with the frequent development of systemic disease. (Grade A/Level IIii)

Mycosis Fungoides and Sézary Syndrome

Also see Table below.

• Skin-directed therapy (topical therapy, superficial radiotherapy, and phototherapy) is appropriate treatment for patients with early stages of mycosis fungoides (stages IA-IIA) with the choice of therapy dependent on the extent of cutaneous disease and plaque thickness. (Grade A/Level I)
• Combined psoralen + ultraviolet A (PUVA) and alpha-interferon therapy can be effective for patients with resistant early-stage disease (stage IB-IIA). (Grade A/Level IIi)
• Patients with later stages of mycosis fungoides (stage IIB or higher) will require some form of systemic therapy. (Grade A/Level IIii)
• CTCL is a very radiosensitive malignancy and several fractions (2-3) of low energy (80-120 kV) superficial radiotherapy are appropriate for many patients. (Grade A/Level IIii)
• Chemotherapy regimens in advanced stages of mycosis fungoides generally achieve complete responses in the region of 30% but these are short-lived. (Grade B/Level IIii)
• Erythrodermic CTCL patients should be considered for immunotherapy and extracorporeal photopheresis (ECP), as responses to chemotherapy are generally poor. (Grade A/Level IIii)
• Total skin electron beam (TSEB) therapy is an effective treatment for stage IB and stage III mycosis fungoides but is not sufficient alone for stage IIB disease or those with significant haematological involvement. (Grade A/Level IIi)
• New agents such as bexarotene and denileukin diftitox offer important therapeutic alternatives which are currently being evaluated. (Grade A/Level IIii)
• In treatment-resistant cases of late stage disease, palliative radiotherapy and/or chemotherapy may produce a significant short-term benefit but the patient's quality of life should always be given priority. (Grade B/Level III)
• All patients and especially those with late stages of disease (>IIA) should be considered for entry into well designed randomized controlled clinical trials.

Table. Treatment of mycosis fungoides/Sézary syndrome

PBSCT, peripheral blood stem cell transplant; ECP, extracorporeal photopheresis; TSEB, total skin electron beam; PUVA, psoralen + ultraviolet A; SDT, skin-directed therapy including topical emollients, steroids, mechlorethamine, carmustine, bexarotene gel, UVB/PUVA, superficial radiotherapy. Stage III includes Sézary syndrome, although some cases of Sézary syndrome will be stage IVA. ECP is ideal for those patients with peripheral blood involvement.

*Not yet licensed in Europe.

Definitions:

Levels of Evidence

I: Evidence obtained from at least one properly designed, randomized controlled trial

II-I: Evidence obtained from well designed controlled trials without randomization

II-ii: Evidence obtained from well designed cohort or case-control analytic studies, preferably from more than one centre or research group

II-iii: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.

III: Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees

IV: Evidence inadequate owing to problems of methodology (e.g. sample size, or length or comprehensiveness of follow-up or conflicts of evidence)

Recommendation Grades

1. There is good evidence to support the use of the procedure.
2. There is fair evidence to support the use of the procedure.
3. There is poor evidence to support the use of the procedure.
4. There is fair evidence to support the rejection of the use of the procedure.
5. There is good evidence to support the rejection of the use of the procedure.

None provided

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations").

Not applicable: The guideline was not adapted from another source.

2003 Dec

British Association of Dermatologists - Medical Specialty Society

British Association of Dermatologists

U.K. Cutaneous Lymphoma Group (UKCLG)

Primary Authors: S.J. Whittaker, St. John's Institute of Dermatology, St. Thomas' Hospital, London; J.R. Marsden, Department of Dermatology, Selly Oak Hospital, Birmingham; M. Spittle, Department of Oncology, Middlesex Hospital, Mortimer St; R. Russell Jones, Department of Dermatology, Ealing Hospital, Southall

Dr Sean J. Whittaker has previously acted as an expert witness for Ligand Pharmaceuticals with regard to European licensing applications for bexarotene gel and denileukin diftitox.

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI on April 19, 2005. The information was verified by the guideline developer on June 27, 2005. This summary was updated by ECRI on March 24, 2006 following the U.S. Food and Drug Administration (FDA) advisory on Ontak (denileukin diftitox).

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.